Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience

doi:10.5306/wjco.v11.i5.283

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5895)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

290

WORD

142

HTML

3279

Figures (1-3)

387

Tables (1-4)

306

Sum=4404

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

606

Download

885

Sum=1491

May 24, 2020 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. May 24, 2020; 11(5): 283-293
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.283

Table 1 Clinical and histopathological characteristics of human epidermal growth factor receptor 2 positive and human epidermal growth factor receptor 2 negative invasive lobular carcinomas patients, n (%)

Characteristics	HER2+ (n = 87)	HER2- (n = 777)		Total (n = 864)	P value
Age (yr)					1.000
≤ 50	30 (34.5)	272 (35.0)		302 (35.0)
> 50	57 (65.5)	505 (65.0)		562 (65.0)
Ethnicity					0.594
Chinese	68 (78.2)	558 (72.1)		626 (72.7)
Indian	4 (4.6)	60 (7.8)		64 (7.4)
Malay	8 (9.2)	68 (8.8)		76 (8.8)
Others	7 (8.0)	88 (11.4)		95 (11.0)
ER					< 0.001
Negative	21 (24.4)	46 (5.9)		67 (7.8)
Positive	65 (75.6)	730 (94.1)		795 (7.8)
PR					0.002
Negative	35 (40.2)	185 (24.0)		220 (25.6)
Positive	52 (59.8)	587 (76.0)		639 (74.4)
Tumour size					0.765
0.1-2 cm	21 (41.2)	230 (38.7)		251 (38.9)
> 2 cm	30 (58.8)	365 (61.3)		395 (61.1)
Tumour grade					<0.001
Grade 1	7 (10.1)	148 (22.5)		155 (21.3)
Grade 2	42 (60.9)	443 (67.3)		485 (66.7)
Grade 3	20 (29.0)	67 (10.2)		87 (12.0)
Tumour stage					0.066
Stage 1	20 (24.1)	216 (30.3)		236 (29.7)
Stage 2	25 (30.1)	267 (37.5)		292 (36.7)
Stage 3	27 (32.5)	179 (25.1)		206 (25.9)
Stage 4	11 (13.3)	50 (7.0)		61 (7.7)
Treatment
Chemotherapy¹	50 (66.7)	390 (54.2)		440 (55.3)	0.038
With HER2 therapy	47 (54.0)	-	-	47 (54.0)
No HER2 therapy	12 (13.8)	-	-	12 (13.8)
Unknown if any HER2 therapy	28 (32.2)	-	-	28 (32.2)
Radiotherapy²	47 (62.7)	404 (56.1)		451 (56.7)	0.276
Surgery³	73 (92.4)	690 (92.1)		763 (92.1)	0.929

¹There were 69 patients with unknown chemotherapy histories which were excluded from analysis.

²There were 69 patients with unknown radiotherapy histories which were excluded from analysis.

³There were 36 patients with unknown surgery histories which were excluded from analysis. HER2: Human epidermal growth factor receptor 2; HER2+: Human epidermal growth factor receptor 2 positive; HER2-: Human epidermal growth factor receptor 2 negative; ER: Estrogen receptor; PR: Progesterone receptor.

Citation: Kee GJ, Tan RYC, Rehena S, Lee JJX, Zaw MWW, Lian WX, Yeong J, Tan SM, Lim SH, Tan BKT, Yap YS, Dent RA, Wong FY, Lee GE. Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience. World J Clin Oncol 2020; 11(5): 283-293
URL: https://www.wjgnet.com/2218-4333/full/v11/i5/283.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i5.283